Navigation Links
Gene variation may elevate risk of liver tumor in patients with cirrhosis
Date:1/1/2008

A particular gene variation appears to significantly increase the risk that individuals with cirrhosis of the liver will go on to develop hepatocellular carcinoma (HCC), a liver tumor that is the third leading cause of cancer death. In the January 2 Journal of the American Medical Association, researchers from Massachusetts General Hospital (MGH) Cancer Center and colleagues in France describe finding that a single alteration in the epidermal growth factor (EFG) gene may greatly increase the risk of developing HCC.

If these results are confirmed, this EGF variation could be used to determine which cirrhotic patients should be screened more intensively for tumor development, says Kenneth Tanabe, MD, chief of Surgical Oncology at the MGH Cancer Center, the studys lead author. In addition, the molecular pathway controlled by EGF and its receptor EGFR which is known to be important in several types of cancer appears to be an excellent target for chemoprevention studies. This is a deadly cancer and so progress in prevention and early detection is critically important.

HCC is the sixth most common solid tumor worldwide and most commonly develops in individuals with cirrhosis, which may be caused by infection with the hepatitis B or C viruses. There are currently no effective treatments for most HCC patients, so there is considerable interest in strategies that may prevent development of the tumor.

EGFs normal function is to stimulate tissue growth. Animal studies have shown that elevated levels of this protein in the liver lead to tumor development and that blocking the proteins receptor can prevent development of liver cancer. The current study was designed to determine whether cirrhotic patients with higher EGF levels are at greater risk for liver cancer and to determine the influence of a particular inherited gene on EGF levels in cirrhotic patients.

The researchers focused on a known variation in the EGF gene th
'/>"/>

Contact: Stacy Neale
sneale@partners.org
617-643-3907
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New book presents successful strategies for probing genetic variation
2. Physician-scientists seek solutions to reproductive problems related to chromosomal variations
3. Copy number variation may stem from replication misstep
4. Survey finds elevated rates of new asthma among WTC rescue and recovery workers
5. Elevated nitric oxide in blood is key to high altitude function for Tibetans
6. Elevated carbon dioxide changes soil microbe mix below plants
7. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
8. Clearance of hepatitis C viral infection after liver transplantation
9. Targeting nerve growth factor may cure liver cancer
10. Mountain pine beetle: Canadas new government delivers
11. Using green chemistry to deliver cutting-edge drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... past several decades have led to heritable, genetic changes ... according to University of Oregon evolutionary geneticists. , Writing ... of SCIENCE, William E. Bradshaw, professor of biology, and ... populations have changed genetically in response to rapid climate ...
... years, scientists have identified a new genus of a living ... Science May 11 in the online Science Express. , ... of discovery' is by no means over," says William Stanley, ... The Field Museum, where the world's only specimen of this ...
... Kavli Institute of Nanoscience have discovered how to use ... on a chip. Based on this, they built a ... molecules individually. To demonstrate this, the Delft researchers sorted ... of the University of Florida has called the Delft ...
Cached Biology News:Recent, rapid climate change is driving evolution of animal species 2Scientists describe new African monkey genus ?first in 83 years 2Scientists describe new African monkey genus ?first in 83 years 3Biological motors sort molecules one by one on a chip 2
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive menstrual ... available new FDA approved system in the last 14 years, and the only endometrial ... (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and the ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... studies at the International Spine Intervention Society’ s 23rd Annual Scientific ... August 1st, 2015. With a focus on evidence-based research and clinical application, the ...
(Date:8/27/2015)... ... August 27, 2015 , ... The ... funds, investment firms and animal health companies to hear from animal health companies ... Several have also received licensing agreements or distribution contracts. This meeting is ...
(Date:8/27/2015)... PARK, Calif. , Aug. 27, 2015  Asterias ... in the emerging field of regenerative medicine, today announced ... investor conferences in the month of September.  ... will present at Rodman & Renshaw,s 17th Annual Global ... ET/7:25am PT at the St. Regis Hotel in ...
Breaking Biology Technology:U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2
... ROUGE, La., Sept. 10 Drug discovery and development ... enrollment and dosing of patients in a Phase 1 ... EP-100, the lead candidate from Esperance,s Cationic Lytic Peptide ... designed to seek and destroy cancer cells that over-express ...
... TAI,AN, Shandong, China, Sept. ... Bulletin Board: CBPO) ("China Biologic," or the,"Company"), ... in the,People,s Republic of China ("PRC"), operating ... Products Co. Ltd.,("Taibang") and Chongqing Dalin Biologic ...
... CORK, Ireland, September 10 Hovione announced today that,Terry Lambe, Ph.D., ... , Hovione acquired earlier this year an ... of the Hovione strategy to become a,leading manufacturer to the pharmaceutical ... Terry Lambe to Hovione. We want to build our,Cork site into ...
Cached Biology Technology:Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer 2Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer 3China Biologic Products to Attend at Susquehanna's Third Annual Beijing Management Summit 2China Biologic Products to Attend at Susquehanna's Third Annual Beijing Management Summit 3Hovione Appoints Terry Lambe to its Board of Directors 2